Key result
In-hospital HFimpEF is linked to ~68% lower 1-year mortality compared to non-improved LVEF.
Why the study?
In-hospital trajectories of LVEF in patients admitted for acute heart failure have been poorly investigated.
Does heart failure with improved ejection fraction (HFimpEF) at predischarge reduce the risk of mortality in patients admitted for acute heart failure with LVEF ≤40%?
Cohort (n=779)
No
Does heart failure with improved ejection fraction (HFimpEF) at predischarge reduce the risk of mortality in patients admitted for acute heart failure with LVEF ≤40%?
Early in-hospital improvement of LVEF in acute heart failure strongly predicts improved short- and long-term survival, indicating that discharge LVEF provides more accurate prognostic information than admission LVEF.
Discharge LVEF >40% may refine 1-year mortality risk stratification in acute HF; hypothesis-generating and requires prospective validation before practice change.
Background The in‐hospital trajectories of left ventricular ejection fraction (LVEF) in patients admitted for acute heart failure have been poorly investigated. We sought to assess the rate of heart failure with improved ejection fraction (HFimpEF) at discharge in acute heart failure, to identify predictors of HFimpEF and to evaluate the association of HFimpEF with outcome. Methods We retrospectively enrolled patients admitted for acute heart failure, with ≥2 in‐hospital echocardiographic evaluations of LVEF and with LVEF ≤40% at admission. HFimpEF was defined as LVEF >40% at discharge, with an improvement in LVEF ≥10%. The primary end point was 1‐year all‐cause death. Trajectories of LVEF were also assessed at follow‐up ambulatory visit at 1 year after discharge. Results The overall population included 779 patients with LVEF ≤40% at admission; at discharge, 14.9% had HFimpEF. The independent predictors of HFimpEF were valvular heart disease (odds ratio, 3.460; P =0.001), lower left ventricular volumes (odds ratio, 0.957 per 1 mL/m 2 increase; P <0.001), and absence of right ventricular dysfunction (odds ratio, 0.518; P =0.017). LVEF at admission was not associated with 1‐year all‐cause death. When patients were classified according to the in‐hospital LVEF trajectory, HFimpEF was independently associated with a lower risk of 1‐year (hazard ratio [HR], 0.324; P =0.008) and 5‐year all‐cause death (HR, 0.584; P =0.013). Among patients discharged with HFimpEF who were reevaluated after 12 months, 86% maintained LVEF >40%, while 14% showed again LVEF ≤40%. Conclusions In patients with acute heart failure admitted with LVEF ≤40%, 15% had HFimpEF at predischarge reassessment. Valvular pathogenesis of heart failure with reduced ejection fraction, absent right ventricular dysfunction and less severe left ventricular remodeling were associated with higher likelihood of in‐hospital HFimpEF. One‐year and 5‐year mortality risk was lower in patients with HFimpEF compared with patients with nonimproved LVEF.
No takes yet. Share an insight, caveat, or question.
Cocianni et al. (2026) conducted a cohort in Acute Heart Failure with LVEF ≤40% (n=779). Heart failure with improved ejection fraction (HFimpEF) at predischarge vs. Non-improved ejection fraction was evaluated on 1-year all-cause death (HR 0.324, 95% CI 0.141-0.741, p=0.008). In-hospital heart failure with improved ejection fraction (LVEF >40%) reduced the risk of 1-year all-cause death compared to non-improved ejection fraction (HR 0.324).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: